原发灶全剂量立体定向体部放疗联合纵隔放化疗治疗局部晚期非小细胞肺癌:计划实用指南、2期研究剂量学结果及3期NRG Oncology LU-008试验治疗计划指南
研究详细报告了从CT模拟定位到治疗计划与实施的全程技术指南及剂量学结果,原发灶立体定向体部放疗主要采用容积旋转调强技术。≥2级肺炎与肺V5 Gy>70%相关,≥2级肺毒性(原文写作pulmonary toxicity)与肺V10 Gy>50%相关;仅3例(5%)发生≥3级肺炎,仅1例(1.7%)发生3级食管炎。
要点
- 原发灶SBRT 50-54 Gy分3-5次后,受累淋巴结常规分割放化疗60 Gy分2 Gy,联合双药化疗。
- ≥2级肺炎与肺V5 Gy>70%相关,≥2级肺毒性(原文写作pulmonary toxicity)与肺V10 Gy>50%相关。
- 仅3例(5%)发生≥3级肺炎,仅1例(1.7%)发生3级食管炎。
核心结论
- 原发灶SBRT后受累淋巴结常规分割放化疗按所述计划技术可行,该2期研究放疗相关毒性低。
- 本文为已启动的NRG Oncology LU-008 3期试验评估该实验性方案提供指南。
研究设计与样本
- 2期多中心单臂研究,2017年至2022年入组60例III期或不可切除II期非小细胞肺癌患者。
- 原发灶SBRT 50-54 Gy分3-5次,随后受累淋巴结常规分割放化疗60 Gy分2 Gy联合双药化疗。
- 符合条件的患者接受度伐利尤单抗辅助治疗至多12个月。
- 报告60例完成治疗患者的靶区覆盖与正常结构剂量,并分析放疗相关毒性与剂量学参数的相关性。
主要发现
- 原发灶SBRT主要采用容积旋转调强,受累淋巴结常规分割放疗主要采用容积旋转调强,少数病例采用动态适形弧技术或静态动态多叶准直器调强放疗。
- ≥2级肺炎与肺V5 Gy>70%相关,≥2级肺毒性(原文写作pulmonary toxicity)与肺V10 Gy>50%相关。
- ≥3级肺炎仅3例(5%)。
- ≥2级食管炎与食管剂量相关,包括平均剂量>20 Gy、V60 Gy>7%和D1cc>55 Gy。
- 3级食管炎仅1例(1.7%)。
关键数值与推荐
- 原发灶SBRT剂量50-54 Gy分3-5次。
- 受累淋巴结常规分割放化疗60 Gy分2 Gy。
- ≥2级肺炎与肺V5 Gy>70%相关。
- ≥2级肺毒性(原文写作pulmonary toxicity)与肺V10 Gy>50%相关。
- ≥2级食管炎与食管平均剂量>20 Gy、V60 Gy>7%、D1cc>55 Gy相关。
临床怎么用
- 本2期研究采用原发灶SBRT 50-54 Gy分3-5次后受累淋巴结常规分割放化疗60 Gy分2 Gy联合双药化疗的方案。
- 原发灶SBRT主要采用容积旋转调强,少数病例采用动态适形弧技术或静态动态多叶准直器调强放疗。
- 符合条件的患者接受度伐利尤单抗辅助治疗至多12个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) has been used with high effectiveness in early-stage non-small cell lung cancer (NSCLC) but has not been studied extensively in locally advanced NSCLC. We conducted a phase 2 study delivering SBRT to the primary tumor followed by conventionally fractionated chemoradiation to the involved lymph nodes for patients with node-positive locally advanced NSCLC. This manuscript serves as both a guide to planning techniques used on this trial and the subsequent phase 3 study, NRG Oncology LU-008, and to report patient dosimetry and toxicity results. METHODS AND MATERIALS: We initiated a phase 2 multicenter single arm study evaluating SBRT to the primary tumor (50-54 Gy in 3-5 fractions) followed by conventionally fractionated chemoradiation to 60 Gy in 2 Gy fractions with doublet chemotherapy to the involved lymph nodes for patients with stage III or unresectable stage II NSCLC. Patients eligible for adjuvant immunotherapy received up to 12 months of durvalumab. We report a detailed guide for the entire treatment process from computed tomography simulation through treatment planning and delivery. The dosimetric outcomes from the 60 patients who completed therapy on study are reported both for target coverage and normal structure doses. We also report correlation between radiation-related toxicities and dosimetric parameters. RESULTS: Sixty patients were enrolled between 2017 and 2022. Planning techniques used were primarily volumetric modulated arc therapy for SBRT to the primary tumor and conventionally fractionated radiation to the involved nodes, with a minority of cases using dynamic conformal arc technique or static dynamic multileaf collimator intensity modulated radiation therapy. Grade 2 or higher pneumonitis was associated with lung dose V5 Gy > 70% and grade 2 or higher pulmonary toxicity was associated with lung dose V10 Gy > 50%. Only 3 patients (5%) experienced grade 3 or higher pneumonitis. Grade 2 or higher esophagitis was associated with esophageal doses, including mean dose > 20 Gy, V60 Gy > 7%, and D1cc > 55 Gy. Only 1 patient (1.7%) experienced grade 3 esophagitis. CONCLUSIONS: SBRT to the primary tumor followed by conventionally fractionated chemoradiation to the involved lymph nodes is feasible with planning techniques as described. Radiation-related toxicity on this phase 2 study was low. This manuscript serves as a guideline for the recently activated NRG Oncology LU-008 phase 3 trial evaluating this experimental regimen.
引用
- Heinzerling JH, Pen OV, Robinson M, et al. Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial. Pract Radiat Oncol. 2023. PMID: 37406774. doi:10.1016/j.prro.2023.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。